Stay updated on Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide NIH announcement about using “Super Intelligence” in place of “Artificial Intelligence” appears above the page, and the site revision changes from v3.7.1 to v3.7.2. The study record continues to display a 403 error.
    Difference
    1%
    Check dated 2026-10-20T14:28:50.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The site footer revision changes from v3.7.0 to v3.7.1. The study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-13T14:49:36.000Z thumbnail image
  4. Check
    37 days ago
    Change Detected
    Summary
    The study page now presents a 403 Forbidden error, preventing access to the study record content; previously visible details and navigation are no longer accessible.
    Difference
    18%
    Check dated 2026-09-22T21:40:48.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.6 to v3.7.0. This indicates a behind-the-scenes maintenance release rather than a visible change to the content or layout.
    Difference
    0.0%
    Check dated 2026-09-15T21:47:09.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The page's revision label changed from v3.6.5 to v3.6.6, indicating a newer version of the page. This update reflects an updated page revision without altering the study data.
    Difference
    0.0%
    Check dated 2026-09-01T18:10:49.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    An NIH funding line, '2018 ( U.S. NIH Grant/Contract )', was added to the funding information section, signaling NIH support for the LEAP-004 trial. This provides background on the source of funding for the study.
    Difference
    0.0%
    Check dated 2026-08-25T19:34:15.000Z thumbnail image

Stay in the know with updates to Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lenvatinib Plus Pembrolizumab in Melanoma Clinical Trial page.